ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for discussion Register to chat with like-minded investors on our interactive forums.

BIOQ Bioqual Inc (PK)

72.50
0.00 (0.00%)
02 May 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type
Bioqual Inc (PK) USOTC:BIOQ OTCMarkets Common Stock
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.00% 72.50 72.50 79.00 0.00 13:27:41

BIOQUAL Presents Financial Results for Fiscal Year 2014 and Declares Dividend

14/11/2014 4:56pm

Business Wire


Bioqual (PK) (USOTC:BIOQ)
Historical Stock Chart


From May 2019 to May 2024

Click Here for more Bioqual (PK) Charts.

BIOQUAL:

       

2014

2013

Revenue $ 21,579,740 $ 20,204,308   (Loss) Income Before Income Tax $ 1,495,164 $ (107,016 )   Net (Loss) Income $ 868,201 $ (87,244 )  

Basic (Loss) Earnings per Share of Common Stock

$

.97

$

(.10

)

 

Diluted (Loss) Earnings per Share of Common Stock

$

.97

$

(.10

)

 

Weighted Average Number of Shares Outstanding For Basic Earnings

893,470 894,934  

Weighted Average Number of Shares Outstanding For Diluted Earnings

893,470 894,934  

BIOQUAL’s Board of Directors has declared a dividend of $0.20 per share for shareholders of record on November 28, 2014, payable on December 15, 2014. This is the thirteenth dividend declared by BIOQUAL.

Statements herein that are not descriptions of historical facts are forward-looking and subject to risk and uncertainties. Actual results could differ materially from those currently anticipated due to a number of factors including risks relating to the ability to continue to extend current government contracts and obtain new contracts; the actual cost incurred in performing its contracts; uncertainties relating to clinical trials; dependence on third parties; and future capital needs.

BIOQUALMark G. Lewis, Ph.D., CEO301-251-2801www.bioqual.com

1 Year Bioqual (PK) Chart

1 Year Bioqual (PK) Chart

1 Month Bioqual (PK) Chart

1 Month Bioqual (PK) Chart

Your Recent History

Delayed Upgrade Clock